Drugging p53: Barriers, Criteria, and Prospects

Area of Science:

• Oncology
• Molecular Biology
• Drug Discovery

Background:

• The tumor suppressor p53 is the most frequently mutated protein in human cancers.
• Conventional drug strategies focus on inhibition, but p53 mutations often lead to loss-of-function, requiring restoration.
• Targeting mutant p53 has remained a significant challenge in cancer pharmacotherapy.

Purpose of the Study:

• To re-evaluate the scientific logic and address misconceptions surrounding p53 function-restoration strategies.
• To identify key barriers hindering the development of drugs targeting mutant p53.
• To propose criteria for evaluating the effectiveness and clinical translation of mutant p53 rescue compounds.

Main Methods:

• Literature review and critical analysis of existing scientific approaches to p53 targeting.
• Identification and categorization of barriers to drugging mutant p53.
• Development of a framework for evaluating potential p53 rescue compounds.

Main Results:

• Identified four primary barriers impeding the development of mutant p53 therapeutics.
• Challenged existing paradigms and misconceptions in the field of p53 research.
• Proposed novel criteria for assessing the efficacy and clinical viability of p53-restoring agents.

Conclusions:

• A function-restoration strategy is essential for pharmacologically targeting mutant p53.
• Overcoming identified barriers is crucial for advancing mutant p53 rescue compound development.
• The proposed evaluation criteria and norms will guide future research and clinical translation efforts.